Monthly Prescribing Reference

Pneumococcal Vaccine Schedule: High Risk Pediatrics

1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...
Nasdaq

U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13® ...
FiercePharma

Playing catch-up with Merck, Pfizer scores pediatric approval for Prevnar 20

With its next-generation pneumococcal vaccine, Pfizer has been playing catch-up with Merck in the indication’s key age group—infants. Thursday, Pfizer got to the finish line 10 months after its rival, ...
MM&M

Pfizer’s Prevnar 20 gets FDA greenlight for treating kids, infants

The Food and Drug Administration approved Prevnar 20, Pfizer’s next-generation 20-valent pneumococcal conjugate vaccine, for treating infants and children under the age of 17. The announcement ...
Nasdaq

Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and commercialize next-generation pneumococcal conjugate vaccines (PCVs) for treating ...